AstraZeneca, IBM ink $1.4B IT deal
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
AstraZeneca |
IBM |
$1.4B deal |
IBM has inked a $1.4 billion, seven-year deal to manage AstraZeneca's IT infrastructure around the globe. |
|
Merck |
Ariad |
$1B development pact |
The companies inked a deal for AP23573 mTOR inhibitor, which is scheduled to begin a late-stage study for metastatic sarcomas. |
|
AstraZeneca |
Silence Therapeutics |
$400M deal |
Silence Therapeutics has partnered up with AstraZeneca in the early stage identification and development of siRNA molecules. |
|
Noven Pharmaceuticals |
JDS Pharmaceuticals |
$125M acquisition deal |
Noven Pharmaceuticals is paying $125 million in cash and assuming $10 million in debt to clinch a deal to acquire New York-based JDS Pharmaceuticals. |
|
Warburg Pincus |
Inspire Pharmaceuticals |
$75M stock purchase |
Warburg Pincus is buying $75 million worth of Inspire Pharmaceuticals' stock, which gives the company a fresh injection of capital. |
|
Genentech |
Tercica |
$53M deal |
Tercica is partnering with Genentech on two new combinatorial therapies. |